Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Organizational Evolution: Balancing Exploration & Development

Posted on April 26th, 2017 by

Pharma R&D

Elsevier Reset Therapies 27

Rubius Therapeutics had an extraordinary 2016. We were able to dramatically progress our work on the technology platform (where we expanded the number of different ways that we can express proteins) Continue reading “Organizational Evolution: Balancing Exploration & Development” »

Making Precision Medicine a Reality

Posted on April 24th, 2017 by

Chemistry

Precision medicine white paper

Precision medicine is no longer just a promising new development discussed only by medical professionals and industry insiders at conferences and in journals. In early 2015, former U.S. President Barack Obama announced the $215 million Precision Medicine Initiative Continue reading “Making Precision Medicine a Reality” »

Assessing Our Progress and Looking Ahead

Posted on April 21st, 2017 by

The Hive

Reset video still

Like many start-ups, Reset Therapeutics has been driven by big ideas, which we have pursued with passion, commitment and accountability. Continue reading “Assessing Our Progress and Looking Ahead” »

Reaxys: Increasing Efficiency in the Lab

Posted on April 19th, 2017 by

Chemistry

Bruce Clapham

Bruce Clapham is Director and Head of Medicinal Chemistry at the San Francisco-based Reset Therapeutics, a start-up dedicated to using the body’s natural circadian system to discover and develop new therapies. “My job is to run the chemistry lab and to be a leader in the design of new molecules Continue reading “Reaxys: Increasing Efficiency in the Lab” »

New Small Molecule Approaches in Immunotherapy

Posted on April 17th, 2017 by

Chemistry

blood-20745_640

Therapeutic approaches based on small molecules have driven progress in the treatment of chronic diseases such as hypertension and lipid disorders for decades and advances are now being made in new areas Continue reading “New Small Molecule Approaches in Immunotherapy” »

New Reaxys: A Model of Agile Development

Posted on April 11th, 2017 by

Chemistry

Reaxys for blog

The development of a chemistry research solution is not something that should occur solely in the IT department of the product owner. Without the participation of the intended end users of the product, how can the developers be sure that they’re addressing real needs? Continue reading “New Reaxys: A Model of Agile Development” »

  1. 1
  2. 2
  3. 3
  4. 36


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.